Zurueck zur Suche

Reporte zur Charge MN7XR

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

3Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CO 2 IA 1

VAERS 2103902

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge MN7XR

gering
Staat
CO
Alter
54,0
Geschlecht
F
Eingang
11.02.2022
Impfdatum
07.02.2022
Beginn
07.02.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered

Symptomtext

Expired Dose administration; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 54-year-old female patient who received HBV (Engerix B) (batch number MN7XR, expiry date 18th January 2022) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. On 7th February 2022, the patient received Engerix B and Engerix B Pre-Filled Syringe Device. On 7th February 2022, unknown after receiving Engerix B and Engerix B Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were provided as follows: The case was reported by the Medical assistant. The reporter stated that, the patient received an expired dose of Engerix B, which led to expired vaccine used. The Vaccine administration facility was the same as Primary reporter. The reporter consented to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2095877

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge MN7XR

gering
Staat
CO
Alter
54,0
Geschlecht
F
Eingang
08.02.2022
Impfdatum
07.02.2022
Beginn
07.02.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Expired product administered No adverse event

Symptomtext

Patient was administered an expired vaccine, no known reactions.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
none
Vorgeschichte
Diabetes and RA
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 1228069

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge MN7XR

gering
Staat
IA
Alter
31,0
Geschlecht
F
Eingang
19.04.2021
Impfdatum
01.12.2019
Beginn
01.12.2019
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration

Symptomtext

dose 1 engerix-9/27/19 dose 2 engeix-12/01/19 (late); This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 31-year-old female patient who received HBV (Engerix B) (batch number MN7XR, expiry date 18th January 2022) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. Previously administered products included Engerix B (received 1st dose on 27th September 2019). On 1st December 2019, the patient received the 2nd dose of Engerix B and Engerix B Pre-Filled Syringe Device. On 1st December 2019, unknown after receiving Engerix B and Engerix B Pre-Filled Syringe Device, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were provided as follows: The patient received 2nd dose of Engerix B later than the recommended interval, which led to lengthening of vaccination schedule. On 27th January 2020, he patient received 3rd dose of Heplisav instead of Engerix B. No reactions were reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-